<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9741">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01671605</url>
  </required_header>
  <id_info>
    <org_study_id>090846</org_study_id>
    <nct_id>NCT01671605</nct_id>
  </id_info>
  <brief_title>Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation</brief_title>
  <official_title>Mechanisms of CKD-Induced Foam Cell Formation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is currently little understanding of macrophage cholesterol homeostasis and foam cell
      formation across the spectrum of CKD. We hypothesize that an inverse relationship exist
      between the severity of CKD and processes underlying foam cell formation, and that the
      relationship becomes independent of serum lipoprotein levels as renal function declines. We
      propose to systematically examine scavenger receptors and cholesterol uptake as well as
      cholesterol transporters and efflux mechanisms in individuals with normal renal function,
      patients with moderate CKD and those with ESRD-HD. We further propose to determine if
      processed contributing to foam cell formation are related to the plasma lipid profile and if
      the relationship is modified by co-morbidities, such as diabetes, obesity, systemic
      inflammation which are common in this population and directly influence vascular integrity.
      These data will be critically important to understand when the abnormality starts and will
      provide crucial information.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>In vitro lipoprotein functions</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>ESRD on hemodialysis</arm_group_label>
    <description>Patients with ESRD on hemodialysis(CKD stage V) (ESRD-HD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD not on dialysis</arm_group_label>
    <description>Patients with CKD not on dialysis (CKD III-IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Controls with normal kidney function (Control)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ESRD on hemodialysis (CKD stage V) (ESRD-HD)

        Patients with CKD not on dialysis (CKD III-IV)

        Controls with normal kidney function (Control)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with moderate degree of CKD, or patients with advanced CKD who
        have progressed to ESRD requiring maintenance dialysis, or control subjects with intact
        kidney function

        Male or female

        All ethnic groups

        â‰¥ 18 years and have signed informed consent

        For ESRD-HD subjects:  &gt; 6 months of hemodialysis

        Exclusion Criteria:

        Pregnancy and current smoking

        BMI &gt; 45

        Rheumatoid arthritis and systemic lupus erythematosus

        History of active or chronic hepatitis B, history of active or chronic hepatitis C, human
        immunodeficiency virus (HIV)

        For moderate CKD subjects: nephrotic syndrome

        For control subjects: nephrotic syndrome, patients with estimated GFR &lt; 60 mL/min/1.73
        m^2, or proteinuria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentina Kon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt Outpatient Dialysis Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Kon, MD</last_name>
      <phone>615-322-4883</phone>
      <email>valentina.kon@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Valentina Kon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>August 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Valentina Kon</investigator_full_name>
    <investigator_title>Principal Investigatro</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
